Literature DB >> 11115536

Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.

A Elnemr1, T Ohta, A Yachie, M Kayahara, H Kitagawa, I Ninomiya, S Fushida, T Fujimura, G Nishimura, K Shimizu, K Miwa.   

Abstract

The aim of this study was to investigate the expression and functional status of Fas ligand (FasL) and its receptor (Fas) in human pancreatic cancers. Using RT-PCR and Western blotting, Fas and FasL were expressed in seven surgically resected pancreatic cancer specimens and five cell lines; Capan-1, AsPC-1, BxPC-3, PANC-1, and MIA PaCa-2. In the resected specimens, pancreatic cancer cells induced apoptosis in the surrounding lymphoid cells. In coculture experiments of pancreatic cancer and Jurkat T cells, 50% of Jurkat T cells underwent apoptosis after 2 days, however, almost all pancreatic cancer cells remained viable. In addition, by testing Fas function using anti-Fas antibody (CH11), all cell lines were resistant to Fas-mediated apoptosis except Capan-1 cells which showed sensitivity similar to that of Jurkat T cells. These results suggest that pancreatic cancer cells evade immune surveillance by expression of FasL and non-functioning Fas that allow them to activated T-cells. These tumor escape mechanisms may contribute to the rapid fatal course of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11115536

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

Review 1.  Apoptosis: a review of programmed cell death.

Authors:  Susan Elmore
Journal:  Toxicol Pathol       Date:  2007-06       Impact factor: 1.902

Review 2.  Immunotherapy in gastrointestinal cancers.

Authors:  Patrick Grierson; Kian-Huat Lim; Manik Amin
Journal:  J Gastrointest Oncol       Date:  2017-06

3.  Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis.

Authors:  Julie Guillermet; Nathalie Saint-Laurent; Philippe Rochaix; Olivier Cuvillier; Thierry Levade; Andrew V Schally; Lucien Pradayrol; Louis Buscail; Christiane Susini; Corinne Bousquet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-18       Impact factor: 11.205

4.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

5.  ARK5 expression in colorectal cancer and its implications for tumor progression.

Authors:  Gen-ichi Kusakai; Atsushi Suzuki; Tsutomu Ogura; Sin'ichi Miyamoto; Atsushi Ochiai; Michio Kaminishi; Hiroyasu Esumi
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

6.  Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.

Authors:  Mengsen Li; Xinhua Liu; Sheng Zhou; Pingfeng Li; Gang Li
Journal:  BMC Cancer       Date:  2005-08-05       Impact factor: 4.430

Review 7.  Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.

Authors:  Chin-King Looi; Felicia Fei-Lei Chung; Chee-Onn Leong; Shew-Fung Wong; Rozita Rosli; Chun-Wai Mai
Journal:  J Exp Clin Cancer Res       Date:  2019-04-15

8.  The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Aaron T Wild; Xiaobu Ye; Susannah G Ellsworth; Jessica A Smith; Amol K Narang; Tanu Garg; Jian Campian; Daniel A Laheru; Lei Zheng; Christopher L Wolfgang; Phuoc T Tran; Stuart A Grossman; Joseph M Herman
Journal:  Am J Clin Oncol       Date:  2015-06       Impact factor: 2.339

Review 9.  Inflammatory Cytokine Signaling during Development of Pancreatic and Prostate Cancers.

Authors:  Geou-Yarh Liou
Journal:  J Immunol Res       Date:  2017-12-12       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.